CAMBRIDGE, UK – 22 September 2026

o2h Discovery is pleased to announce that Stevenage Bioscience Catalyst has joined its Platinum Partner Programme, enabling eligible life science companies within the SBC’s portfolio to access the o2h Kickstarter Award and integrated drug discovery support designed to accelerate early-stage therapeutic development.

Through the Platinum Partner Programme, eligible companies within the Stevenage Bioscience Catalyst portfolio will gain access to the o2h Kickstarter Award and integrated drug discovery support, including medicinal chemistry, peptide discovery, biology, ADME and project management expertise designed to accelerate early-stage therapeutic development.

Backed by o2h Discovery’s integrated drug discovery platform and team of more than 800 scientists, the o2h Kickstarter Award has supported more than 40 biotechnology startups across the UK, USA, Europe, Australia and Israel, helping founders generate critical scientific data, achieve key technical milestones and strengthen future fundraising efforts. 

Marco Delise, Director of Entrepreneurship and Business Development at SBC, commented:

Collaboration is at the heart of what we do at Stevenage Bioscience Catalyst. Our partnership with o2h Discovery gives the early-stage companies in our community access to additional drug discovery expertise and chemistry support at a point when it can make a real difference. By connecting our companies with specialist partners like o2h Discovery, we can help them accelerate their science, reach critical milestones and ultimately bring promising new therapies closer to patients.

Sunil Shah, Co-founder of o2h Discovery, commented:

The o2h Kickstarter Award was created to help early-stage biotech companies access the scientific expertise and discovery capabilities needed to reach their next milestone. Over the past few years, we’ve had the privilege of supporting 50 startups globally, and the Platinum Partner Program is a natural extension of that journey. We are delighted to welcome Stevenage Bioscience Catalyst as a Platinum Partner and look forward to working together to help more founders accelerate their science and build successful biotechnology companies.

Together, Stevenage Bioscience Catalyst and o2h Discovery aim to help promising biotech companies move more efficiently from early scientific discovery towards investment readiness, value creation and ultimately new therapies for patients.

—————————————————————————————–

About Stevenage Bioscience Catalyst

Stevenage Bioscience Catalyst (SBC) is a leading UK biotech cluster of therapeutics companies, located in a campus including GSK and the Cell and Gene Therapy Catapult. SBC combines flexible laboratory infrastructure with hands-on commercial support, helping innovative startups connect with investors, pharmaceutical partners, and the expertise needed to accelerate the development of new healthcare solutions. A total of £4bn have been attracted by companies on site in the last 10 years, including proceeds from 7 exits.

For more information, visit: http://www.stevenagecatalyst.com

About o2h Discovery

Founded in 2005, o2h Discovery operates an integrated drug discovery platform across Cambridge, UK and Ahmedabad, India. With expertise spanning medicinal chemistry, biology, DMPK, peptide discovery, scale-up chemistry and project management, o2h Discovery supports biotechnology and pharmaceutical companies from hit identification through lead optimisation and into IND-enabling studies. For more information, visit: www.o2hdiscovery.co

About the o2h Kickstarter Award

Launched in 2022, the o2h Kickstarter Award was created to provide a chemistry and discovery boost to early-stage biotech companies developing novel therapeutics. The programme supports companies that have secured initial funding and are seeking to generate critical scientific data ahead of their next funding milestone.

Since launch, the programme has completed multiple international editions across the UK, USA, Europe, Australia and Israel, supporting 50 biotechnology companies globally. Award recipients receive access to dedicated chemistry teams, integrated discovery expertise and project management support designed to accelerate early-stage drug discovery programmes. For more information, visit https://o2h.com/the-o2h-kickstarter-competition/ 

About the o2h Discovery Platinum Partner Programme

The o2h Discovery Platinum Partner Programme enables venture capital firms, venture builders, incubators, accelerators, technology transfer offices and innovation ecosystems to extend the benefits of the o2h Kickstarter Award directly to eligible portfolio companies and ventures. By combining investment, strategic guidance and integrated drug discovery support, the programme helps early-stage biotechnology companies generate the scientific data needed to achieve critical technical, commercial and fundraising milestones.

Through this collaborative model, Platinum Partners can offer their founders access to medicinal chemistry, peptide synthesis services (peptide drug discovery), PR&D and scale-up services, biology, ADME and project management expertise at a stage where scientific progress is often constrained by limited resources. The programme reflects o2h Discovery’s commitment to strengthening the global biotech innovation ecosystem by helping more promising therapies progress from early discovery towards meaningful clinical and commercial outcomes. For more information, visit: https://o2h.com/o2h-discovery-platinum-partner/ 

———————————————————

Media Contact
Mayank Gupta
Marketing Manager
Platinum Partner Programme
o2h Discovery